PTPN11 and neoplasm: SHP2 modulates tumor immunosuppression by negatively regulating type I interferon signaling and allosteric inhibition of SHP2 remolds the anti-tumor TME in CRC patients, indicating SHP2 is a promising target for CRC immunotherapy (45).